| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
EDTA hydrate sodium does not have a defined pharmacological target as it is a chelating agent and biochemical reagent. The compound chelates metal ions by forming stable complexes with divalent and trivalent cations such as calcium, magnesium, iron, and zinc. As a chelator, it can sequester metal ions that are essential cofactors for enzymes, thereby inhibiting metal-dependent enzymatic activities. Its primary applications are in biochemical research and as a formulation excipient.
|
|---|---|
| ln Vitro |
In vitro activity of EDTA hydrate sodium is assessed in metal ion chelation assays. The compound is used to remove metal ions from solutions, to prepare metal-free buffers, and to inhibit metal-dependent enzymes. It is commonly used in cell culture media, protein purification, and molecular biology applications. The compound's chelating activity is typically measured by its ability to bind specific metal ions and prevent their participation in enzymatic or chemical reactions.
|
| ln Vivo |
No specific in vivo pharmacological activity data have been documented for EDTA hydrate sodium as a therapeutic agent. EDTA derivatives have been used clinically for metal chelation therapy in cases of heavy metal poisoning. The compound is used primarily as a biochemical reagent and formulation excipient. If used in animal studies, it would be administered via appropriate routes for metal chelation studies or as a formulation component.
|
| Enzyme Assay |
For non-cellular assays, EDTA hydrate sodium is characterized by standard analytical techniques including HPLC and titration to confirm identity and purity. The compound can be evaluated for its metal chelation capacity using various analytical methods including titration with metal ion solutions, spectrophotometric assays, or chromatographic methods. Purity is typically ≥98%. Solubility: 1M NaOH: soluble, clear, colorless to light yellow. The compound is a crystalline powder.
|
| Cell Assay |
For in vitro cell-based studies, EDTA hydrate sodium is used as a component of cell culture media and buffers. It is typically dissolved in aqueous buffers and added to media at appropriate concentrations to chelate metal ions. Cells are cultured under standard conditions in media containing EDTA for various applications including cell dissociation (as a component of trypsin-EDTA solutions) and metal ion depletion studies. Appropriate controls should be included in the experimental design.
|
| Animal Protocol |
For in vivo animal studies, EDTA hydrate sodium can be administered via various routes including intravenous, intraperitoneal, or oral administration for metal chelation studies. The compound is also used as a formulation excipient in pharmaceutical preparations. Dosing solutions should be freshly prepared using appropriate vehicles. Standard animal welfare guidelines should be followed for all in vivo studies.
|
| ADME/Pharmacokinetics |
EDTA hydrate sodium has a molecular weight of 376.20 and molecular formula C10H15N2Na3O9. It appears as a crystalline powder. Solubility: 1M NaOH: soluble, clear, colorless to light yellow. Storage: store at room temperature, keep dry and cool. In solvent: stable at -80°C for 2 years or -20°C for 1 year. The compound has an MDL number of MFCD00149675.
|
| Toxicity/Toxicokinetics |
EDTA hydrate sodium is for research use only and not for human consumption. Standard laboratory safety practices should be followed when handling this chemical. EDTA compounds are generally considered to have low acute toxicity. Appropriate personal protective equipment including gloves and safety glasses should be worn. Specific LD50 values and detailed toxicological profiles have been established for regulatory purposes.
|
| Additional Infomation |
EDTA hydrate sodium (CAS 85715-60-2) is also known as ethylenediaminetetraacetic acid trisodium salt hydrate, (ethylenedinitrilo)tetraacetic acid trisodium salt hydrate, and EDTA trisodium salt hydrate. It has an MDL number of MFCD00149675. The compound is used as a chelating agent, biochemical reagent, and formulation excipient. No clinical trials or therapeutic approvals exist for this specific hydrate form.
|
| Molecular Formula |
C10H13N2NA3O8.XH2O
|
|---|---|
| Molecular Weight |
358.19 (anhydrous basis)
|
| Exact Mass |
376.047
|
| CAS # |
85715-60-2
|
| PubChem CID |
16211179
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
300ºC
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
24
|
| Complexity |
351
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Na].O=C(CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)O.O
|
| InChi Key |
KKTNQJMZBPLVKM-UHFFFAOYSA-K
|
| InChi Code |
InChI=1S/C10H16N2O8.3Na.H2O/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;;;1H2/q;3*+1;/p-3
|
| Chemical Name |
trisodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxymethyl)amino]acetate;hydrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
